This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor | MicrobiomeTrials
← Back to trials NCT05523947
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-08-26Est. Completion: 2028-03-31
Enrollment target: 147 participantsLocations Dana Farber Cancer Institute, Boston, Massachusetts, United States Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States Southern Oncology Clinical Research Unit, Adelaide, Australia Austin Health, Melbourne, Australia Breast Cancer Research Centre - WA, Perth, Australia Blacktown Hospital, Sydney, Australia CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, South Korea Catholic University of Korea St. Vincent's Hospital, Suwon, Gyeonggi-do, South Korea Ajou University Hospital, Suwon, Gyeonggi-do, South Korea Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, South Korea Chungbuk National University Hospital, Cheongju-si, North Chungcheong, South Korea Gachon Gil University Medical Center, Incheon, South Korea Korea University Anam Hospital, Seoul, South Korea Seoul National University Hospital, Seoul, South Korea Severance Hospital, Yonsei University Health System, Seoul, South Korea Asan Medical Center, Seoul, South Korea Other microbiome trials you might be interested in Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
This is a multicenter, non-interventional, descriptive study to retrospectively collect solid tumor samples from focused…
Beijing, China Est. completion Dec 31, 2026
HER2-positive Breast Cancer Recurrent Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer
Samsung Medical Center, Seoul, South Korea
The Catholic University of Korea, St. Mary's hospital, Seoul, South Korea
Ulsan University Hospital, Ulsan, South Korea Breast Adenocarcinoma
Inflammatory Breast Carcinoma
This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation…
Duarte, United States Completed Jan 12, 2021
Locally Advanced or Metastatic Malignant Solid Tumors
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed …
Tucson, United States Est. completion Feb 25, 2025